The two fatalities are among more than 500 suspected adverse drug reaction reports submitted to the MHRA in relation to weight loss injections used in Northern Ireland. The reports span a range of side effects and complications, with the deaths representing the most serious outcomes recorded. Health authorities have stressed that the reports constitute suspected adverse reactions and do not automatically confirm a direct causal link between the injections and the deaths.
Weight loss injections, including GLP-1 receptor agonist drugs such as semaglutide, marketed under brand names including Ozempic and Wegovy, have surged in popularity in recent years as treatments for obesity. The rapid growth of the market has raised concerns among regulators and healthcare professionals about the use of these medications outside of clinical supervision. Some injections have been obtained through private clinics, online pharmacies, and, in some cases, unregulated sources.
The MHRA has confirmed it is reviewing the reports as part of its standard pharmacovigilance procedures, which involve continuous monitoring of medicines after they reach the market. The agency receives suspected adverse drug reaction reports from healthcare professionals, patients, and carers through its Yellow Card reporting system. Officials have emphasized that the submission of a report does not confirm that a drug caused a particular outcome, but that all reports are taken seriously and investigated accordingly.
Health officials in Northern Ireland have urged anyone using weight loss injections to do so only under the supervision of a qualified healthcare professional. Concerns have been raised about the growing availability of injectable weight loss treatments through unregulated channels, including online platforms that may not carry out adequate medical checks. Patients have been advised to report any unusual symptoms or side effects to their doctor or through the MHRA's Yellow Card scheme immediately.
The MHRA has not issued a formal safety alert or product recall in connection with the reports at this stage. The agency continues to work with healthcare providers and industry partners to monitor the safety profile of weight loss medications as their use continues to expand across the United Kingdom. Further updates are expected as investigations into the two deaths progress.
